Hinge Bio’s Phase I program runs on three Medrio modules simultaneously: EDC, ePRO, and RTSM, a stack the biotech chose specifically to avoid the cost overruns and multi-month setup times that enterprise vendors typically require for first-in-human studies. That choice reflects a real operational trade-off facing lean biotechs: enterprise platforms carry validation infrastructure and negotiating weight, but small sponsors launching a single Phase I often spend more time onboarding the software than enrolling the first cohort.
The timing argument is concrete. Medrio’s RTSM can be deployed in four to five weeks, with mid-study amendments turned around in a week or less. For a Phase I team watching a dose-escalation schedule, a one-week amendment turnaround versus a multi-month one is not a marginal improvement: it determines whether a safety update delays the next cohort or not. Hinge Bio’s clinical operations team, led by Chief Clinical Operations Officer Kristen Quigley alongside clinical data manager Sarah Huntley and clinical lead Joshua Pellam, cites accelerated timelines, predictable costs, and reduced site burden as the outcomes the setup delivered.
The site burden point deserves attention. Phase I trials run at a small number of sites, often academic medical centers with already-stretched coordinators. Consolidating data capture, patient-reported outcomes, and randomization and trial supply management into one vendor means coordinators train on one system rather than three, and the sponsor’s data team troubleshoots one contract. Whether that translates to faster query resolution or fewer screen failures at the site level, the case study does not specify, but the operational logic is sound for a single-program company without a dedicated IT department.
Context worth noting: the FDA’s final decentralized trial guidance, issued in September 2024, increased pressure on sponsors to document how remote data collection tools integrate with site workflows. A unified eClinical platform with a single audit trail addresses that documentation requirement more cleanly than separate vendor systems. For biotechs watching Hinge Bio’s setup, the metric to track is whether single-vendor configurations shorten the gap between protocol amendment approval and first patient enrolled under the revised version at the median site.
Source link: https://medrio.com/case-studies/hinge-bio-phase-i-trial-edc-epro-rtsm-2/
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
